DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
January 28, 2022 at 04:36 am
Share
DongKoo Bio&Pharma Co., Ltd. (KOSDAQ:A006620) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares according to the contract with NH INVESTMENT & SECURITIES CO.,LTD. The purpose of the program is stock price stability and shareholder value enhancement. The program will run until July 27, 2022.
As of January 27, 2022, the company had 425,116 and 0 treasury stock holdings within the available dividend range acquisition and other acquisitions, respectively.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
DONGKOO BIO & PHARMA CO., LTD. 
